The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors
Abstract
This study investigated the role of genetic factors (CYP1A2) in caffeine metabolism. The CYP1A2 activity was determined in 378 Danish twins following oral intake of a single dose of 200 mg caffeine and subsequent determination of the caffeine ratio (AFMU+1MU+1MX)/17DMU in a 6-h urine sample. The mean (+/- SD) caffeine ratio was 5.9 +/- 3.4. The caffeine ratio was statistically significantly higher in men compared to women, in smoking men and women compared to non-smoking persons of the same gender and in women not taking oral contraceptives compared with women on oral contraceptives. Thus, we confirmed that CYP1A2 is more active in men than in women, that it is induced by smoking and inhibited by oral contraceptives. In the subsequent analysis of heritability, we included 49 monozygotic twin pairs and 34 same gender dizygotic twin pairs concordant for non-smoking and non-use of oral contraceptives. The intraclass correlation coefficient was 0.798 (95% confidence interval, 0.696-0.900) and 0.394 (95% confidence interval, 0.109-0.680) in the monozygotic and dizygotic twins, respectively. The correlation was statistically significantly higher (P = 0.0015) in the former compared with the latter. A biometrical model for the caffeine ratio including only additive genetic factors and unique environmental factors was the overall best fitting model. Estimates based on this model gave a heritability estimate of 0.725 (95% confidence interval 0.577-0.822). Unique environmental effects seem to account for the remainder 0.275 (95% confidence interval, 0.178-0.423). Our study shows that the CYP1A2 activity is mainly governed by genetic factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These authors also found a higher CYP1A2 activity in smokers and men than in non-smokers and women, respectively.”
From Scientific Opinion on the safety of caffeine (2015) · cites this paper as Rasmussen et al., 2002
In the citing paper
“CYP1A2 polymorphism has been reported to be a source of variability in the metabolism of caffeine between individuals measured by caffeine metabolites in urine (Rasmussen et al., 2002).”
From Scientific Opinion on the safety of caffeine (2015) · cites this paper as Rasmussen et al., 2002
In the citing paper
“A lower CYP1A2 activity was found in women taking oral contraceptives.”
From Scientific Opinion on the safety of caffeine (2015) · cites this paper as Rasmussen et al., 2002
Citations
Cites
Akaike, H. (1987) · Psychometrika · doi:10.1007/bf02294359 · Cited by 5,264
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadée, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
A twin-pronged attack on complex traits
Martin, N. G., Boomsma, D. I., & Machin, G. A. (1997) · Nature Genetics · doi:10.1038/ng1297-387 · Cited by 654
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M. F., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. H. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 363
Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy
Alexanderson, B., Evans, D. A. P., & Sjöqvist, F. (1969) · BMJ · doi:10.1136/bmj.4.5686.764 · Cited by 360
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 345
Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
Diaz, D., Fabrev, I., Daujat‐Chavanieu, M., Saint‐Aubert, B., Bories, P., Michel, H., & Maurel, P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90963-2 · Cited by 308
Science, medicine, and the future: Pharmacogenetics
Wolf, C. R. (2000) · BMJ · doi:10.1136/bmj.320.7240.987 · Cited by 287
Furuya, H., Fernández‐Salguero, P. M., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 277
Eaton, D. L., Gallagher, E. P., Bammler, T. K., & Kunze, K. L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199510000-00001 · Cited by 271
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
KALOW, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 264
Variability in caffeine metabolism
Grant, D. M., Tang, B. K., & KALOW, W. (1983) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1983.80 · Cited by 257
Sesardic, D., Boobis, A. R., Edwards, R., & Davies, D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03393.x · Cited by 233
Genetic Control of Drug Levels in Man: Antipyrine
Vesell, E. S., & Page, J. G. (1968) · Science · doi:10.1126/science.161.3836.72 · Cited by 220
Impairment of Caffeine Clearance by Chronic Use of Low-Dose Oestrogen-Containing Oral Contraceptives
Abernethy, D. R., & Todd, E. L. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544361 · Cited by 195
A urinary metabolite ratio that reflects systemic caffeine clearance
Campbell, M. E., Spielberg, S. P., & KALOW, W. (1987) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1987.126 · Cited by 192
Genetic Control of Drug Levels in Man: Phenylbutazone
Vesell, E. S., & Page, J. G. (1968) · Science · doi:10.1126/science.159.3822.1479 · Cited by 177
Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine
Vistisen, K. K., Poulsen, H. E., & Loft, S. H. (1992) · Carcinogenesis · doi:10.1093/carcin/13.9.1561 · Cited by 174
Expression of CYP1A1 and CYP1A2 genes in human liver
Schweikl, H., Taylor, J. A., Kitareewan, S., Linko, P., Nagorney, D. M., & Goldstein, J. A. (1993) · Pharmacogenetics · doi:10.1097/00008571-199310000-00003 · Cited by 165
Genetic control of dicumarol levels in man
Vesell, E. S., & Page, J. G. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105949 · Cited by 153
Rasmussen, B., Mäenpää, J., Pelkonen, O., Loft, S. H., Poulsen, H. E., Lykkesfeldt, J., & Brøsen, K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04422.x · Cited by 150
Pharmacogenetics of tolbutamide metabolism in humans
Scott, J., & Pl, P. (1979) · Diabetes · doi:10.2337/diabetes.28.1.41 · Cited by 139
Caffeine Intake, Tolerance, and Withdrawal in Women: A Population-Based Twin Study
Kendler, K. S., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.223 · Cited by 125
Schrenk, D., Brockmeier, D., Mörike, K., Bock, K. W., & Eichelbaum, M. F. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050394 · Cited by 116
The caffeine CO2 breath test: Dose response and route of N-demethylation in smokers and nonsmokers
Kotake, A. N., Schoeller, D. A., Lambert, G. H., Baker, A. L., Schaffer, D. D., & Josephs, H. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.157 · Cited by 102
Rasmussen, B. B., & Brøsen, K. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199606000-00006 · Cited by 80
Decreased Concentration of Phenacetin in Plasma of Cigarette Smokers
Pantuck, E. J., Kuntzman, R. G., & Conney, A. H. (1972) · Science · doi:10.1126/science.175.4027.1248 · Cited by 77
Monozygotic twins concordant for response to clozapine
Vojvoda, D., Grimmell, K., Sernyak, M. J., & Mazure, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91594-9 · Cited by 68
Cytochrome P450 and therapeutic drug monitoring with respect to clozapine
Buur-Rasmussen, B., & Brøsen, K. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00033-4 · Cited by 60
Polymorphism of theophylline metabolism in man.
Miller, C. A., Slusher, L. B., & Vesell, E. S. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111843 · Cited by 58
DIPHENYLHYDANTOIN HALF‐LIFE IN MAN AND ITS INHIBITION BY PHENYLBUTAZONE: THE ROLE OF GENETIC FACTORS
Andreasen, P. B., Frøland, A., Skovsted, L., Andersen, S. A., & Hauge, M. (1973) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1973.tb10628.x · Cited by 57
Genetic study of amobarbital elimination based on its kinetics in twins
Endrényi, L., Inaba, T., & KALOW, W. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976206701 · Cited by 51
A population and family study of CYP1A2 using caffeine urinary metabolites
Catteau, A., Poisson, N., Bona�ti-Pelli�, C., Bechtel, Y. C., & Bechtel, P. R. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196856 · Cited by 45
Olanzapine: concordant response in monozygotic twins with schizophrenia
Mata, I. F., Madoz, V., Arranz, M. J., Sham, P. C., & Murray, R. M. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.1.86 · Cited by 44
Theophylline metabolism: Variation and genetics
Miller, M. E., Opheim, K. E., Raisys, V. A., & Motulsky, A. G. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.23 · Cited by 39
Theophylline‐rifampicin interaction: non‐selective induction of theophylline metabolic pathways.
Robson, R., Miners, J. O., Wing, L., & Birkett, D. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02487.x · Cited by 37
Methodology for inferences concerning familial correlations: A review
Donner, A. P., & Eliasziw, M. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90084-m · Cited by 26
Research works printed but not linked: 4
- Shimada, 1994, J Pharmacol Exp Ther, 270, 414
- Shahidi, 1967, Am J Dis Child, 113, 81
- Campbell, 1987, Drug Metab Dispos, 15, 237
- Nakajima, 1994, Cancer Epidemiol Biomarkers Prev, 3, 413
Cited by
Sorted by citations
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S., Liu, J., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 857
International society of sports nutrition position stand: caffeine and performance
Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., Taylor, L., Willoughby, D., Stout, J., Graves, B. S., et al. (2010) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-7-5 · Cited by 686
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00383-4 · Cited by 665
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Metadata
- Authors
- Rasmussen
- Venue
- Pharmacogenetics
- Published
- 2002-08-01
- Volume
- 12
- Issue
- 6
- Pages
- 473-478
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W237900477
- Cited by
- 241
- References
- 43
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 8 · 2020: 6 · 2019: 12 · 2018: 11 · 2017: 6 · 2016: 10 · 2015: 9 · 2014: 10 · 2013: 12 · 2012: 13
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- caffeine metabolism, CYP1A2, heritability, monozygotic twins, dizygotic twins, smoking, oral contraceptives, sex differences, genetic and environmental factors
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Biotransformation, Caffeine, Chromatography, High Pressure Liquid, Contraceptives, Oral, Hormonal, Female, Humans, Male, Middle Aged, Sex Factors, Smoking, Twins, Dizygotic, Twins, Monozygotic, Cytochrome P-450 CYP1A2, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review